deal
Bristol Myers Squibb acquires Karuna Therapeutics for $14bn
BMS has acquired Karuna's lead asset, KarXT (xanomeline-trospium), along with its early-stage and pre-clinical pipeline.
BMS has acquired Karuna's lead asset, KarXT (xanomeline-trospium), along with its early-stage and pre-clinical pipeline.